What does APOTHEEK ROOSEN do?

APOTHEEK ROOSEN is a logistics company in Genk. Private Limited, started on 4 February 1987, 1 establishment.

What is the address of APOTHEEK ROOSEN?

The registered office of APOTHEEK ROOSEN is located at Sledderlo 50, 3600 Genk.

Is APOTHEEK ROOSEN still active?

Yes. According to the CBE (29 October 2026) APOTHEEK ROOSEN is active, legal situation “Normale toestand”, started on 4 February 1987.

Is APOTHEEK ROOSEN registered on Peppol?

Yes, APOTHEEK ROOSEN is registered on the Peppol network with ID 0208:0430444725.

What is the enterprise number of APOTHEEK ROOSEN?

The enterprise number of APOTHEEK ROOSEN is BE0430444725.

When was APOTHEEK ROOSEN founded?

APOTHEEK ROOSEN was founded on 4 February 1987.

Who are the directors of APOTHEEK ROOSEN?

According to the 2025 annual accounts, the directors of APOTHEEK ROOSEN are: Nicolas Meuwissen, Myriam Roosen, Paul Meuwissen.

Is APOTHEEK ROOSEN a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 4 February 1987; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did APOTHEEK ROOSEN make in 2025?

APOTHEEK ROOSEN posted a profit after taxes of € 111,004 in financial year 2025.

What is the revenue of APOTHEEK ROOSEN?

As a small company, APOTHEEK ROOSEN is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 330,099.

How much does an employee at APOTHEEK ROOSEN earn?

The average wage cost per full-time employee at APOTHEEK ROOSEN was € 73,700 in 2025: staff costs of € 132,575 for 1.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does APOTHEEK ROOSEN have?

According to the 2025 annual accounts, APOTHEEK ROOSEN has 1.8 full-time equivalents (FTE).

APOTHEEK ROOSEN (Private Limited) - Genk - BE0430444725

Dossier APOTHEEK ROOSEN, printed on 29 October 2026 from databakkes.be/en/0430444725/apotheek-roosen. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

APOTHEEK ROOSEN from Genk, company number BE0430444725, closed financial year 2025 with a result of € 111,004 after tax. For that financial year APOTHEEK ROOSEN recorded a gross margin of € 330,099 and equity of € 824,503. Compared with financial year 2024, the result moved from € 141,360 to € 111,004. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 11, 2026.

What it is worth Growing

€ 824,503

▲ 16% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 111,004

▼ 21% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 327,661

▲ 15% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 805,903.

People and assets in 2025

Full-time equivalents

1.8

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 132,575

▲ 14% vs 2024

€ 73,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 36,196

▼ 21% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 9 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 352,068

€ 39,269 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.

Owed to suppliers

€ 55,029

▲ 7% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 26,437

▼ 1% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 357,381 Gross margin 2022: € 357,381 First fiscal year in the series	€ 304,861 Gross margin 2023: € 304,861 ▼ 15% vs 2022 (€ 357,381) Unfavourable step	€ 351,601 Gross margin 2024: € 351,601 ▲ 15% vs 2023 (€ 304,861) Favourable step	€ 330,099 Gross margin 2025: € 330,099 ▼ 6% vs 2024 (€ 351,601) Unfavourable step	▼ 6%
Profit after taxes	€ 143,554 Profit after taxes 2022: € 143,554 First fiscal year in the series	€ 110,211 Profit after taxes 2023: € 110,211 ▼ 23% vs 2022 (€ 143,554) Unfavourable step	€ 141,360 Profit after taxes 2024: € 141,360 ▲ 28% vs 2023 (€ 110,211) Favourable step	€ 111,004 Profit after taxes 2025: € 111,004 ▼ 21% vs 2024 (€ 141,360) Unfavourable step	▼ 21%
Equity	€ 567,602 Equity 2022: € 567,602 First fiscal year in the series	€ 631,479 Equity 2023: € 631,479 ▲ 11% vs 2022 (€ 567,602) Favourable step	€ 713,499 Equity 2024: € 713,499 ▲ 13% vs 2023 (€ 631,479) Favourable step	€ 824,503 Equity 2025: € 824,503 ▲ 16% vs 2024 (€ 713,499) Favourable step	▲ 16%
Total debts	€ 208,125 Total debts 2022: € 208,125 First fiscal year in the series	€ 156,795 Total debts 2023: € 156,795 ▼ 25% vs 2022 (€ 208,125) Favourable step	€ 134,011 Total debts 2024: € 134,011 ▼ 15% vs 2023 (€ 156,795) Favourable step	€ 476,522 Total debts 2025: € 476,522 ▲ 256% vs 2024 (€ 134,011) Unfavourable step	▲ 256%
Cash	€ 471,155 Cash 2022: € 471,155 First fiscal year in the series	€ 447,081 Cash 2023: € 447,081 ▼ 5% vs 2022 (€ 471,155) Unfavourable step	€ 285,974 Cash 2024: € 285,974 ▼ 36% vs 2023 (€ 447,081) Unfavourable step	€ 327,661 Cash 2025: € 327,661 ▲ 15% vs 2024 (€ 285,974) Favourable step	▲ 15%
Land & buildings	€ 10,854 Land & buildings 2022: € 10,854 First fiscal year in the series	€ 9,600 Land & buildings 2023: € 9,600 ▼ 12% vs 2022 (€ 10,854) Unchanged	€ 8,347 Land & buildings 2024: € 8,347 ▼ 13% vs 2023 (€ 9,600) Unchanged	€ 29,896 Land & buildings 2025: € 29,896 ▲ 258% vs 2024 (€ 8,347) Unchanged	▲ 258%
Retained profit	€ 549,002 Retained profit 2022: € 549,002 First fiscal year in the series	€ 612,879 Retained profit 2023: € 612,879 ▲ 12% vs 2022 (€ 549,002) Favourable step	€ 694,899 Retained profit 2024: € 694,899 ▲ 13% vs 2023 (€ 612,879) Favourable step	€ 805,903 Retained profit 2025: € 805,903 ▲ 16% vs 2024 (€ 694,899) Favourable step	▲ 16%
Dividend	€ 54,133 Dividend 2022: € 54,133 First fiscal year in the series	€ 46,333 Dividend 2023: € 46,333 ▼ 14% vs 2022 (€ 54,133) Unchanged	€ 59,339 Dividend 2024: € 59,339 ▲ 28% vs 2023 (€ 46,333) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 59,339) Unchanged	▼ 100%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 352,068 Bank debt 2025: € 352,068 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 775,727 Balance sheet total 2022: € 775,727 First fiscal year in the series	€ 788,274 Balance sheet total 2023: € 788,274 ▲ 2% vs 2022 (€ 775,727) Unchanged	€ 847,510 Balance sheet total 2024: € 847,510 ▲ 8% vs 2023 (€ 788,274) Unchanged	€ 1,301,025 Balance sheet total 2025: € 1,301,025 ▲ 54% vs 2024 (€ 847,510) Unchanged	▲ 54%
Employees (FTE)	1.7 Employees (FTE) 2022: 1.7 First fiscal year in the series	1.8 Employees (FTE) 2023: 1.8 ▲ 0.1 vs 2022 (1.7) Unchanged	1.8 Employees (FTE) 2024: 1.8 Unchanged (1.8) Unchanged	1.8 Employees (FTE) 2025: 1.8 Unchanged (1.8) Unchanged

Key figures of APOTHEEK ROOSEN, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to APOTHEEK ROOSEN?

What happened at APOTHEEK ROOSEN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 11, 2026 New annual accounts for financial year 2025: profit of € 111,004 (▼ 21% vs 2024). Source: NBB ↗
2022 Nicolas Meuwissen became a director. NBB
2022 Myriam Roosen became a director. NBB
2022 Paul Meuwissen became a director. NBB
Mar 11, 1987 New establishment in Genk. KBO
Feb 4, 1987 Start of the company according to the CBE. KBO

In short

From € 143,554 profit in 2022 to € 111,004 profit in 2025.

Paid € 221,076 in corporate taxes since 2022.

Best year ever: 2022, with € 143,554 profit.

On average € 183,400 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Nicolas Meuwissen Myriam Roosen Paul Meuwissen

FEBELCO

APOTHEEK ROOSEN

APOTHEEK SYNAPS PARK

Verenigde Apothekers Genk

Behind APOTHEEK ROOSEN are Nicolas Meuwissen, Myriam Roosen and Paul Meuwissen. Nicolas Meuwissen is also behind FEBELCO. Paul Meuwissen is also behind APOTHEEK SYNAPS PARK and Verenigde Apothekers Genk.

Directors

According to the 2025 annual accounts

Nicolas Meuwissen

Director

Also active at: FEBELCO

since 2022

Myriam Roosen

Director

since 2022

Paul Meuwissen

Director

Also active at: APOTHEEK SYNAPS PARK, Verenigde Apothekers Genk

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Sledderlo 50

3600 Genk

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0430.444.725

VAT number

BE 0430.444.725

Registered office

Sledderlo 50, 3600 Genk

Names & denominations

APOTHEEK ROOSEN

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

4 February 1987

Peppol

Active · Active since 26 Jun 2025

Activities · NACE

Apothekers

Detailhandel in farmaceutische producten

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten

Computerconsultancy-activiteiten

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

APOTHEEK ROOSEN

Financials

What happened to APOTHEEK ROOSEN?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions